- Home
- MA vs JNJ Comparison
MA vs JNJ Comparison
Compare MA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MA
- JNJ
- Stock Information
- Founded
- MA 1966
- JNJ 1886
- Country
- MA United States
- JNJ United States
- Employees
- MA N/A
- JNJ N/A
- Industry
- MA Business Services
- JNJ Biotechnology: Pharmaceutical Preparations
- Sector
- MA Consumer Discretionary
- JNJ Health Care
- Exchange
- MA Nasdaq
- JNJ Nasdaq
- Market Cap
- MA 495.7B
- JNJ 449.6B
- IPO Year
- MA 2006
- JNJ 1944
- Fundamental
- Price
- MA $544.62
- JNJ $196.87
- Analyst Decision
- MA Strong Buy
- JNJ Buy
- Analyst Count
- MA 26
- JNJ 16
- Target Price
- MA $647.31
- JNJ $196.19
- AVG Volume (30 Days)
- MA 2.6M
- JNJ 7.6M
- Earning Date
- MA 10-30-2025
- JNJ 10-14-2025
- Dividend Yield
- MA 0.56%
- JNJ 2.65%
- EPS Growth
- MA 18.23
- JNJ 71.26
- EPS
- MA 15.64
- JNJ 10.35
- Revenue
- MA $31,474,000,000.00
- JNJ $92,149,000,000.00
- Revenue This Year
- MA $19.70
- JNJ $6.62
- Revenue Next Year
- MA $12.44
- JNJ $5.28
- P/E Ratio
- MA $34.89
- JNJ $18.93
- Revenue Growth
- MA 15.60
- JNJ 5.08
- 52 Week Low
- MA $465.59
- JNJ $140.68
- 52 Week High
- MA $601.77
- JNJ $197.18
- Technical
- Relative Strength Index (RSI)
- MA 38.07
- JNJ 70.57
- Support Level
- MA $548.01
- JNJ $185.12
- Resistance Level
- MA $565.91
- JNJ $187.83
- Average True Range (ATR)
- MA 10.17
- JNJ 2.91
- MACD
- MA 0.05
- JNJ 0.59
- Stochastic Oscillator
- MA 16.10
- JNJ 92.13
About MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $10 trillion in volume during 2024. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.